Laying Out Analysis of Raludotatug Deruxtecan Dose Optimisation in Patients with Platinum-Resistant Ovarian Cancer

• Overviewing R-DXd design and mechanism of action
• Presenting clinical activity of R-DXd in patients with platinum-resistant ovarian cancer (PROC) from Phase I and Phase II/III REJOICE-Ov01 study
• Exploring the outcome of dose optimisation analysis of R-DXd in patients with PROC

Speakers:

Guillaume Bergthold

Executive Director, Clinical Development

Daiichi Sankyo